Unknown

Dataset Information

0

Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial.


ABSTRACT:

Background

Compromised iron status is important in restless legs syndrome pathophysiology. We compared the efficacy and tolerability of ferric carboxymaltose (single intravenous dose) versus placebo for restless legs syndrome treatment in iron-deficient nonanemic patients.

Methods

Patients with moderate to severe restless legs syndrome and serum ferritin < 75 ?g/L (or serum ferritin 75-300 ?g/L and transferrin saturation < 20%) were randomized to ferric carboxymaltose (1000 mg iron) or placebo. Mean change difference between ferric carboxymaltose and placebo in International Restless Legs Syndrome Severity Scale score from baseline to week 4 was the primary end point; week 12 was a secondary end point.

Results

Ferric carboxymaltose treatment (n = 59) led to nonsignificant improvement over placebo (n = 51) in International Restless Legs Syndrome Severity Scale score at week 4 (difference [95% confidence interval], -2.5 [-5.93 to 1.02], P = 0.163), reaching significance by week 12 (-4.66 [-8.59 to -0.73], P = 0.021).

Conclusions

In patients who responded to treatment, ferric carboxymaltose may require more time to stabilize restless legs syndrome than previously assumed. © 2017 The Authors. Movement Disorders published by Wiley Periodicals, Inc. on behalf of International Parkinson and Movement Disorder Society.

SUBMITTER: Trenkwalder C 

PROVIDER: S-EPMC5655783 | biostudies-literature | 2017 Oct

REPOSITORIES: biostudies-literature

altmetric image

Publications

Ferric carboxymaltose in patients with restless legs syndrome and nonanemic iron deficiency: A randomized trial.

Trenkwalder Claudia C   Winkelmann Juliane J   Oertel Wolfgang W   Virgin Garth G   Roubert Bernard B   Mezzacasa Anna A  

Movement disorders : official journal of the Movement Disorder Society 20170623 10


<h4>Background</h4>Compromised iron status is important in restless legs syndrome pathophysiology. We compared the efficacy and tolerability of ferric carboxymaltose (single intravenous dose) versus placebo for restless legs syndrome treatment in iron-deficient nonanemic patients.<h4>Methods</h4>Patients with moderate to severe restless legs syndrome and serum ferritin < 75 μg/L (or serum ferritin 75-300 μg/L and transferrin saturation < 20%) were randomized to ferric carboxymaltose (1000 mg iro  ...[more]

Similar Datasets

| S-EPMC7205016 | biostudies-literature
| S-EPMC10528926 | biostudies-literature
| S-EPMC6183309 | biostudies-literature
| S-EPMC5947731 | biostudies-literature
| S-EPMC8136455 | biostudies-literature
| S-EPMC6353229 | biostudies-literature
| S-EPMC5406716 | biostudies-literature
| S-EPMC7042864 | biostudies-literature
| S-EPMC5334282 | biostudies-literature
| S-EPMC4209879 | biostudies-literature